SINTX Technologies Inc

Análisis de la acción SINTX Technologies Inc (SINT)

$1.560

-0.058 (-3.70%)Al cierre

Loading chart…
Máximo
1.640
Apertura
1.640
Precio medio ponderado por volumen
1.58
Volumen
41.03K
Capitalización
3.17M
Mínimo
1.550
Importe
64.96K
EV/EBITDA, TTM
-0.31

SINTX Technologies, Inc. is an advanced ceramics company that develops and commercializes materials, components, and technologies for medical and agribiotech applications. It is engaged in the research, development, and manufacturing of silicon nitride. Its core business includes biomedical applications and antipathogenic applications. It has been focused on medical grade silicon nitride. Spinal implants made from its silicon nitride have been implanted in humans. This established use, along with its inherent resistance to bacterial adhesion and bone affinity suggests that it may also be suitable in other fusion device applications such as arthroplasty implants, foot wedges, and dental implants. Its composition of silicon nitride antipathogenic powder may enable manufacturing surfaces that inactivate pathogens, thereby limiting the spread of infection and disease. It manufactures advanced ceramic powders and components in its manufacturing facilities based in Salt Lake City, Utah.

sintx.com

Análisis de IA of SINTX Technologies Inc (SINT)

Vender

SINTX Technologies Inc is not a good buy right now due to its very low RSI of 23.718, indicating oversold conditions, and a significant year-to-date decline of 58.73%. The stock is currently trading at $1.56, which is only 5.2% above its 52-week low of $1.40, suggesting limited upside potential. Additionally, the company has reported substantial net losses, with a net income of -$3,632,000 in Q2 2026, raising concerns about its financial stability. The main risk is its high debt-to-equity ratio of 11.73% in Q1 2026, indicating potential liquidity issues.

Métricas de valoración

El PER previsto actual de SINTX Technologies Inc (SINT) es 0.00, frente a su media de 5 años de -19.40.

PER previsto

Valor razonable
Media 5A P/E
-19.40
P/E actual
0.00
Sobrevalorada
59.35
Infravalorada
-98.14

EV/EBITDA previsto

Valor razonable
Media 5A EV/EBITDA
-0.32
EV/EBITDA actual
-0.31
Sobrevalorada
0.29
Infravalorada
-0.94

Precio/ventas previsto

Valor razonable
Media 5A P/S
4.14
P/S actual
2.03
Sobrevalorada
8.10
Infravalorada
0.19

Escenarios de precio de Alphio AI para SINT

Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.

A

Alcista

Alcista · 25%SINT

$2.63

Precio del escenario

B

Base

Base · 50%SINT

$1.91

Precio del escenario

B

Bajista

Bajista · 25%SINT

$1.46

Precio del escenario

Cronología de eventos

2026-11-05 (ET)

17:30:00

SINTX Technologies Reports Q3 Revenue of $2.19M

2026-10-01 (ET)

09:30:00

Sintx Technologies Reports $2.2M Revenue for Q3

2026-08-13 (ET)

06:30:00

Selling Stockholders Plan to Sell 1.27M Shares of Common Stock

2026-06-25 (ET)

06:30:00

Sintx Technologies Files to Sell 5.82M Shares of Common Stock

2026-06-22 (ET)

10:00:00

Sintx Technologies Secures Over $3.2M in Orders

Noticias

Preguntas frecuentes sobre SINT, respondidas por Alphio AI

SINTX Technologies, Inc. is an advanced ceramics company that develops and commercializes materials, components, and technologies for medical and agribiotech applications. It is engaged in the research, development, and manufacturing of silicon nitride. Its core business includes biomedical applications and antipathogenic applications. It has been focused on medical grade silicon nitride. Spinal implants made from its silicon nitride have been implanted in humans. This established use, along with its inherent resistance to bacterial adhesion and bone affinity suggests that it may also be suitable in other fusion device applications such as arthroplasty implants, foot wedges, and dental implants. Its composition of silicon nitride antipathogenic powder may enable manufacturing surfaces that inactivate pathogens, thereby limiting the spread of infection and disease. It manufactures advanced ceramic powders and components in its manufacturing facilities based in Salt Lake City, Utah. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

SINTX Technologies Inc is not a good buy right now due to its very low RSI of 23.718, indicating oversold conditions, and a significant year-to-date decline of 58.73%. The stock is currently trading at $1.56, which is only 5.2% above its 52-week low of $1.40, suggesting limited upside potential. Additionally, the company has reported substantial net losses, with a net income of -$3,632,000 in Q2 2026, raising concerns about its financial stability. The main risk is its high debt-to-equity ratio of 11.73% in Q1 2026, indicating potential liquidity issues.

Comunidad

Más ↗

Aún no hay publicaciones

Regístrate o inicia sesión para participar

Artículos relacionados

Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.

Empezar a operar